迈威生物-U
(688062)
| 流通市值：51.32亿 | | | 总市值：99.58亿 |
| 流通股本：2.30亿 | | | 总股本：4.47亿 |
| 报告期 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 312,641,623.7 | 127,597,218.83 | 662,515,554.62 | 565,838,248.14 |
| 营业收入 | 312,641,623.7 | 127,597,218.83 | 662,515,554.62 | 565,838,248.14 |
| 二、营业总成本 | 824,538,887.31 | 356,747,236.67 | 1,634,418,367.37 | 1,164,855,191.83 |
| 营业成本 | 76,714,869.52 | 30,432,803.26 | 64,463,671.1 | 38,773,089.89 |
| 税金及附加 | 4,412,918.17 | 1,833,743.99 | 12,100,086.23 | 10,042,665.88 |
| 销售费用 | 139,350,174.32 | 68,909,367.71 | 225,255,980.57 | 153,265,800.26 |
| 管理费用 | 103,645,405.35 | 61,291,320.04 | 268,571,223.41 | 192,243,774.52 |
| 研发费用 | 431,425,639.17 | 164,495,504.99 | 976,960,824.37 | 712,154,824.51 |
| 财务费用 | 68,989,880.78 | 29,784,496.68 | 87,066,581.69 | 58,375,036.77 |
| 其中:利息费用 | 59,774,081.48 | 28,938,739.87 | 90,846,087.76 | 61,678,099.18 |
| 其中:利息收入 | 5,502,554.75 | 2,056,832.13 | 7,609,136.77 | 5,074,031 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | 55,111.12 | - | 1,122,391.35 | 280,597.22 |
| 加:投资收益 | -5,044,913.78 | -3,423,001.22 | -9,601,531.63 | -5,774,855.91 |
| 资产处置收益 | 299,576.7 | 299,576.7 | 199,411.91 | - |
| 资产减值损失(新) | -481,387.49 | -1,209,557.54 | -11,264,036.4 | -9,556,144.94 |
| 信用减值损失(新) | -3,742,967.83 | -6,927,816.57 | 2,525,825 | 2,792,834.32 |
| 其他收益 | 3,943,055.27 | 1,529,272.17 | 33,603,036.52 | 28,337,577.24 |
| 四、营业利润 | -516,868,789.62 | -238,881,544.3 | -955,317,716 | -582,936,935.76 |
| 加:营业外收入 | 3,982.5 | 810 | 2,193,962.73 | 2,193,880.25 |
| 减:营业外支出 | 6,950,392.54 | 1,270,483.52 | 3,269,954.79 | 1,934,551.08 |
| 五、利润总额 | -523,815,199.66 | -240,151,217.82 | -956,393,708.06 | -582,677,606.59 |
| 减:所得税费用 | 389,339.33 | 2,891,629.9 | 15,864,068.18 | 16,919,163.33 |
| 六、净利润 | -524,204,538.99 | -243,042,847.72 | -972,257,776.24 | -599,596,769.92 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | -524,204,538.99 | -243,042,847.72 | -972,257,776.24 | -599,596,769.92 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | -521,707,682.23 | -241,943,587.61 | -969,333,663.43 | -597,660,144.75 |
| 少数股东损益 | -2,496,856.76 | -1,099,260.11 | -2,924,112.81 | -1,936,625.17 |
| 扣除非经常损益后的净利润 | -518,263,473.83 | -241,806,163.16 | -998,855,292.5 | -622,355,445.23 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | -1.26 | -0.61 | -2.43 | -1.5 |
| (二)稀释每股收益 | -1.26 | -0.61 | -2.43 | -1.5 |
| 八、其他综合收益 | -1,934,011.07 | -759,615.5 | -626,593.53 | 2,664.16 |
| 归属于母公司股东的其他综合收益 | -1,934,011.07 | -759,615.5 | -626,593.53 | 2,664.16 |
| 九、综合收益总额 | -526,138,550.06 | -243,802,463.22 | -972,884,369.77 | -599,594,105.76 |
| 归属于母公司股东的综合收益总额 | -523,641,693.3 | -242,703,203.11 | -969,960,256.96 | -597,657,480.59 |
| 归属于少数股东的综合收益总额 | -2,496,856.76 | -1,099,260.11 | -2,924,112.81 | -1,936,625.17 |
| 公告日期 | 2026-08-31 | 2026-04-29 | 2026-03-25 | 2025-10-31 |
| 审计意见(境内) | | | 标准无保留意见 | |